 |
Vol.40 No.2 contents | Japanese/English |
 | Full Text of PDF (96K) Article in Japanese |
- Original Article -
Concurrent high-dose thoracic irradiation plus daily low-dose cisplatin and vindesine in locally advanced unresectable stage III non-small cell lung cancer.
Kikuo Nakano1, Takehiko Hiramoto1, Masasi Kanehara1, Mihoko Doi1, Yosihiro Hada2, Kenji Nakamura31Department of Pulmonary Medicine, National Kure Hospital, 2Department of Radiology, National Kure Hospital, 3Department of Thoracic Surgery, National Kure Hospital
Objective: Patients with unresectable non-small cell lung cancer were treated to evaluate the toxicity and efficacy of high-dose thoracic irradiation (RT) combined with concurrent daily low-dose cisplatin plus vindesine. Methods: Twenty five evaluable patients were treated with continuous-course RT (70 Gy in 35 fractions of 2.0 Gy once daily) and concurrent daily intravenous cisplatin (6 mg/m2) plus vindesine (3 mg/m2 on day 1 and day 8). Results: Leukopenia (48%) was the most severe sign of toxicity, but there were no episodes of discontinuation of treatment. Two patients (8%) had a grade 3 acute radiation esophagitis, but there was no severe late radiation esophagitis. Ten patients experienced late radiation pneumonitis and 9 of those were grade 1 or 2. There was only one life-threatening toxicity (grade 5 pneumonitis). The objective response rate was 72%, and one patient achieved a radiographic complete response. The median survival duration for all patients was 14 months, and the 3-and 5-year actuarial survival rates were 27.2% and 27.2%, respectively. Conclusion: We concluded that the regimen of high-dose thoracic RT combined with concurrent daily low-dose cisplatin plus vindesine was a well-tolerated regimen. The survival results were encouraging.
key words: Non small-cell lung cancer, Low-dose cisplatin, Concurrent chemotherapy, High-dose toracic irradiation
Received: January 20, 2000
Accepted: March 6, 2000
JJLC 40 (2): 111-115, 2000
